Abstract
About 50% of UK patients with beta-thalassaemia major die before the age of 35 years, mainly because conventional iron-chelation therapy is too burdensome for full adherence. Patients require an individually-tailored treatment plan incorporating new, more tolerable approaches.
Publication types
-
Letter
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Adult
-
Chelating Agents / therapeutic use*
-
Chelation Therapy*
-
Child
-
Cohort Studies
-
Deferoxamine / therapeutic use*
-
Humans
-
Iron
-
Patient Compliance
-
Registries
-
Survival Analysis
-
United Kingdom / epidemiology
-
beta-Thalassemia / drug therapy*
-
beta-Thalassemia / mortality*
Substances
-
Chelating Agents
-
Iron
-
Deferoxamine